Skip to main content

Similar reduction in CV risk with different add-on RA treatments

Among patients with active rheumatoid arthritis, adding tumor necrosis factor inhibitors to methotrexate is associated with a similar reduction in vascular inflammation to that seen with add-on sulfasalazine plus hydroxychloroquine, suggest findings from a randomized controlled trial.


Antibody testing may identify cancer patients at increased risk of COVID-19 breakthrough infections

A Canadian population-based study has confirmed that people with cancer have an increased risk of breakthrough COVID-19 infection after vaccination, while UK research points to the feasibility of SARS-CoV-2 antibody testing to identify those with the lowest level of vaccine-derived protection.

Headlines from across medwireNews

01-02-2023 | Oncology | News | Article

FDA approves elacestrant, adds indication for pembrolizumab

Details of these breast and lung cancer decisions available here

30-01-2023 | Oncology | News | Article

EMA recommends new indication for darolutamide

Click through to find out more

30-01-2023 | Rheumatology | News | Article

Anti-dsDNA antibodies could predict response to B cell-targeted therapies in SLE

IgA2 anti-dsDNA antibodies may represent a biomarker of response to B cell-targeted therapies in patients with systemic lupus erythematosus, suggest study findings from Michael Ehrenstein and colleagues.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

27-01-2023 | Oncology | News | Article

Guideline for oncogene-addicted metastatic NSCLC issued by ESMO

Click through for the details of these evidence-based recommendations

26-01-2023 | Diabetes | News | Article

Age 10 years is optimal type 1 diabetes screening point for adolescents

“Almost no one” who is islet autoantibody negative at age 10 years despite a high familial risk for type 1 diabetes will develop clinical diabetes by the age of 18, report researchers.

26-01-2023 | Oncology | News | Article

Adding camrelizumab to chemo prolongs OS of patients with advanced nonsquamous NSCLC

An updated analysis of the CameL trial has shown a significant improvement in overall survival with the addition of camrelizumab to chemotherapy in treatment-naïve Chinese patients with advanced nonsquamous non-small-cell lung cancer.

medwireNews is an established provider of authoritative, timely and independent medical news. We value your feedback and encourage you to contact us to make your preferred medical news resource.